Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):103-109. doi: 10.1182/asheducation-2018.1.103.

Abstract

With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Back Pain / blood
  • Back Pain / diagnosis
  • Back Pain / diagnostic imaging
  • Back Pain / drug therapy
  • Female
  • Humans
  • Ibuprofen / administration & dosage
  • Immunologic Factors / therapeutic use
  • Lumbar Vertebrae / diagnostic imaging
  • Magnetic Resonance Imaging
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / diagnostic imaging
  • Multiple Myeloma / drug therapy*
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Thoracic Vertebrae / diagnostic imaging
  • Tomography, X-Ray Computed

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • elotuzumab
  • daratumumab
  • Thalidomide
  • pomalidomide
  • Ibuprofen